UK markets closed

KROS Jun 2024 65.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
1.75000.0000 (0.00%)
As of 09:30AM EDT. Market open.
Full screen
Previous close1.7500
Open1.7500
Bid0.1500
Ask4.9000
Strike65.00
Expiry date2024-06-21
Day's range1.7500 - 1.7500
Contract rangeN/A
Volume2
Open interest41
  • GlobeNewswire

    Keros Therapeutics to Host a Corporate Update Conference Call and Webcast

    LEXINGTON, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”), today announced that the Company will host a corporate update conference call and webcast on Monday, June 17, 2024 at 8

  • GlobeNewswire

    Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference

    LEXINGTON, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”), today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat prese

  • GlobeNewswire

    Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors

    LEXINGTON, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it appointed Jean-Jacques Bienaimé to its Board of Directors, effective June 1, 2024. “On behal